Π‘ΠΎΡΡΠΎΡΠ½ΠΈΠ΅ ΠΌΠΈΠ½Π΅ΡΠ°Π»ΡΠ½ΠΎΠΉ ΠΏΠ»ΠΎΡΠ½ΠΎΡΡΠΈ ΠΊΠΎΡΡΠ½ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΎΠ±ΡΡΡΡΠΊΡΠΈΠ²Π½ΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΡΡ Π»Π΅Π³ΠΊΠΈΡ
ΠΠΈΡΡΠ΅ΡΡΠ°ΡΠΈΡ
ΠΠ°Π»ΠΈΡΠΈΠ΅ ΠΎΡΡΠ΅ΠΎΠΏΠ΅Π½ΠΈΠΈ ΠΈ ΠΎΡΡΠ΅ΠΎΠΏΠΎΡΠΎΠ·Π°, ΠΏΠΎ Π΄Π°Π½Π½ΡΠΌ Π΄Π΅Π½ΡΠΈΡΠΎΠΌΠ΅ΡΡΠΈΠΈ ΠΏΠΎΡΡΠ½ΠΈΡΠ½ΠΎΠ³ΠΎ ΠΎΡΠ΄Π΅Π»Π° ΠΏΠΎΠ·Π²ΠΎΠ½ΠΎΡΠ½ΠΈΠΊΠ° ΠΈ ΠΏΡΠΎΠΊΡΠΈΠΌΠ°Π»ΡΠ½ΡΡ ΠΎΡΠ΄Π΅Π»ΠΎΠ² Π±Π΅Π΄ΡΠ°, Π²ΡΡΠ²Π»Π΅Π½ΠΎ ΡΡΠ΅Π΄ΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ Π₯ΠΠΠ Ρ 41,3% ΠΈ 38,1% ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎΠ° ΡΡΠ΅Π΄ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΠ Ρ 51,4% ΠΈ 40% ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ, ΡΡΠΎ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ Π²ΡΡΠ΅, ΡΠ΅ΠΌ Π² Π³ΡΡΠΏΠΏΠ΅ ΠΊΠΎΠ½ΡΡΠΎΠ»Ρ (15,6% ΠΈ 12,5% ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ). Π‘ΡΠ΅Π΄Π½ΠΈΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ BMD ΡΠ΅Π½ΡΡΠ°Π»ΡΠ½ΡΡ ΠΎΡΠ΄Π΅Π»ΠΎΠ² ΠΎΡΠ΅Π²ΠΎΠ³ΠΎ ΡΠΊΠ΅Π»Π΅ΡΠ° Π±ΡΠ»ΠΈ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ Π½ΠΈΠΆΠ΅ Π² Π³ΡΡΠΏΠΏΠ°Ρ … Π§ΠΈΡΠ°ΡΡ Π΅ΡΡ >
Π‘ΠΏΠΈΡΠΎΠΊ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ
- «ΠΠΈΠ²Π°Π»ΠΎΡ Π½ΠΎΠ²Π°Ρ ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠ°Ρ ΡΡΡΠ°ΡΠ΅Π³ΠΈΡ Π² Π»Π΅ΡΠ΅Π½ΠΈΠΈ ΠΏΠΎΡΡΠΌΠ΅Π½ΠΎΠΏΠ°ΡΠ·Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΎΡΡΠ΅ΠΎΠΏΠΎΡΠΎΠ·Π°: Π²ΠΎΠΏΡΠΎΡΡ ΠΈ ΠΏΡΡΠΈ ΡΠ΅ΡΠ΅Π½ΠΈΡ.» ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΡΠ°ΡΠ΅Π»ΠΈΡΠ½ΠΎΠ³ΠΎ ΡΠΈΠΌΠΏΠΎΠ·ΠΈΡΠΌΠ° Π² ΡΠ°ΠΌΠΊΠ°Ρ II Π ΠΎΡΡΠΈΠΉΡΠΊΠΎΠ³ΠΎ ΠΊΠΎΠ½Π³ΡΠ΅ΡΡΠ° ΠΏΠΎ ΠΎΡΡΠ΅ΠΎΠΏΠΎΡΠΎΠ·Ρ. Π―ΡΠΎΡΠ»Π°Π²Π»Ρ. 2005, Ρ.Π.
- ΠΠ°ΡΠ°Π½ΠΎΠ²Π° Π.Π. ΠΡΠΎΠ½Ρ ΠΈΠ°Π»ΡΠ½Π°Ρ Π°ΡΡΠΌΠ° ΠΈ ΠΎΡΡΠ΅ΠΎΠΏΠΎΡΠΎΠ·.// Π ΠΠ, 2003, ΡΠΎΠΌ 11, № 22, Ρ. 1229−1234.
- ΠΠ°ΡΠ°Π½ΠΎΠ²Π° Π.Π. ΠΡΡΠ΅ΠΎΠΏΠΎΡΠΎΠ· Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Π±ΡΠΎΠ½Ρ ΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π°ΡΡΠΌΠΎΠΉ: ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈ Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π°ΡΠΏΠ΅ΠΊΡΡ, ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠ° ΠΈ ΠΎΡΠ΅Π½ΠΊΠ° ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ. ΠΠΈΡΡΠ΅ΡΡΠ°ΡΠΈΡ Π½Π° ΡΠΎΠΈΡΠΊΠ°Π½ΠΈΠ΅ ΡΡΠ΅Π½ΠΎΠΉ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ Π΄ΠΎΠΊΡΠΎΡΠ° ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΈΡ Π½Π°ΡΠΊ. ΠΠΎΡΠΊΠ²Π° 2007, 234 Ρ.
- ΠΠ°ΡΠ°Π½ΠΎΠ²Π° Π.Π. ΠΡΡΠ΅ΠΎΠΏΠΎΡΠΎΠ· Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Π±ΡΠΎΠ½Ρ ΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π°ΡΡΠΌΠΎΠΉ: ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈ Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π°ΡΠΏΠ΅ΠΊΡΡ, ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠ° ΠΈ- ΠΎΡΠ΅Π½ΠΊΠ° ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ. ΠΠ²ΡΠΎΡΠ΅ΡΠ΅ΡΠ°Ρ Π΄ΠΈΡΡΠ΅ΡΡΠ°ΡΠΈΠΈ Π½Π° ΡΠΎΠΈΡΠΊΠ°Π½ΠΈΠ΅ ΡΡΠ΅Π½ΠΎΠΉ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ Π΄ΠΎΠΊΡΠΎΡΠ° ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΈΡ Π½Π°ΡΠΊ. ΠΠΎΡΠΊΠ²Π° 2007, 42 Ρ.
- ΠΠ°ΡΠ°Π½ΠΎΠ²Π° Π.Π. Π‘ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½ΠΈΠ΅ ΠΎ Π³Π»ΡΠΊΠΎΠΊΠΎΡΡΠΈΠΊΠΎΠΈΠ΄-ΠΈΠ½Π΄ΡΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΌ ΠΎΡΡΠ΅ΠΎΠΏΠΎΡΠΎΠ·Π΅ ΠΏΡΠΈ Π±ΡΠΎΠ½Ρ ΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π°ΡΡΠΌΠ΅ ΠΈ ΠΏΡΡΠΈ Π΅Π³ΠΎ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠΈ ΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ.// Π ΠΠ, 2004, ΡΠΎΠΌ 12, № 4, Ρ.2−7.
- ΠΠ΅Π½Π΅Π²ΠΎΠ»Π΅Π½ΡΠΊΠ°Ρ Π.Π. ΠΠ±ΡΠΈΠ΅ ΠΏΡΠΈΠ½ΡΠΈΠΏΡ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠΈ ΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΎΡΡΠ΅ΠΎΠΏΠΎΡΠΎΠ·Π°.// Consilium-medicum, 2000, ΡΠΎΠΌ 2, № 2, Ρ 240−244.
- ΠΠ²ΠΎΡΠ΅ΡΠΊΠΈΠΉ Π.Π. Π₯ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΎΠ±ΡΡΡΡΠΊΡΠΈΠ²Π½Π°Ρ Π±ΠΎΠ»Π΅Π·Π½Ρ Π»Π΅Π³ΠΊΠΈΡ ΠΈ ΠΎΡΡΠ΅ΠΎΠΏΠΎΡΠΎΠ·.//Π ΠΠ, 2004, ΡΠΎΠΌ 12, № 14, Ρ. 821−828.
- ΠΠ²ΠΎΡΠ΅ΡΠΊΠΈΠΉ Π.Π. Π₯ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΎΠ±ΡΡΡΡΠΊΡΠΈΠ²Π½Π°Ρ Π±ΠΎΠ»Π΅Π·Π½Ρ Π»Π΅Π³ΠΊΠΈΡ ΠΈ ΠΎΡΡΠ΅ΠΎΠΏΠΎΡΠΎΠ·. Π Π΅Π°Π»ΡΠ½ΡΠΉ Π²ΠΊΠ»Π°Π΄ ΠΈΠ½Π³Π°Π»ΡΡΠΈΠΎΠ½Π½ΡΡ Π³Π»ΡΠΊΠΎΠΊΠΎΡΡΠΈΠΊΠΎΠΈΠ΄ΠΎΠ².// Π ΠΠ, 2006, ΡΠΎΠΌ-14, № 6, Ρ. 422−427.
- ΠΠ²ΠΎΡΠ΅ΡΠΊΠΈΠΉ Π.Π., Π‘Π΅ΡΠ³Π΅Π΅Π²Π° Π. Π. ΠΠ΅ΡΡΠΎ Π³Π»ΡΠΊΠΎΠΊΠΎΡΡΠΈΠΊΠΎΠΈΠ΄ΠΎΠ²1 Π² Π»Π΅ΡΠ΅Π½ΠΈΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ Π₯ΠΠΠ.// Π ΠΠ, 2008, ΡΠΎΠΌ 16, № 7, Ρ.466−470.
- ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°ΡΠΈΠΈ. ΠΡΡΠ΅ΠΎΠΏΠΎΡΠΎΠ·. ΠΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ°, ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠ° ΠΈ Π»Π΅ΡΠ΅Π½ΠΈΠ΅ /ΠΏΠΎΠ΄ ΡΠ΅Π΄. Π. Π. ΠΠ΅Π½Π΅Π²ΠΎΠ»Π΅Π½ΡΠΊΠΎΠΉ. Π. Π. ΠΠ΅ΡΠ½ΡΠΊ Π.:ΠΠΠΠ’ΠΠ -ΠΠ΅Π΄ΠΈΠ°, 2007, Ρ 31.
- ΠΠΎΡΡΡΠ±ΠΈΠΉ Π.Π. ΠΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΎΡΠ΅Π½ΠΊΠ° ΠΊΠΎΡΡΠ½ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ ΠΏΡΠΈ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΎΠ±ΡΡΡΡΠΊΡΠΈΠ²Π½ΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΠΈ Π»Π΅Π³ΠΊΠΈΡ . ΠΠΈΡΡΠ΅ΡΡΠ°ΡΠΈΡ Π½Π° ΡΠΎΠΈΡΠΊΠ°Π½ΠΈΠ΅ ΡΡΠ΅Π½ΠΎΠΉ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ ΠΊΠ°Π½Π΄ΠΈΠ΄Π°ΡΠ° ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΈΡ Π½Π°ΡΠΊ. ΠΠ»Π°Π΄ΠΈΠ²ΠΎΡΡΠΎΠΊ, 2004, 97Ρ.
- ΠΠΎΡΠ΅ΡΠΊΠΎΠ²Π° Π.Π., ΠΠΎΠ»ΠΊΠΎΠ²Π°- MtB. Π€ΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠ΅ ΡΠΎΡΡΠΎΡΠ½ΠΈΠ΅ ΠΊΠΎΡΡΠ½ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ Ρ ΠΊΡΡΡΡΠΈΡ ΠΈ Π½Π΅ΠΊΡΡΡΡΠΈΡ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΎΠ±ΡΡΡΡΠΊΡΠΈΠ²Π½ΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΡΡ Π»Π΅Π³ΠΊΠΈΡ .// Π’Π΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈΠΉ Π°ΡΡ ΠΈΠ², 2005, № 3, Ρ. 14−18.
- ΠΠΎΡΠ΅ΡΠΊΠΎΠ²Π° Π.Π., ΠΠΎΠ»ΠΊΠΎΠ²Π° Π. Π., Π‘ΡΡΠΎΠ²Π΅Π½ΠΊΠΎ Π’. Π., ΠΠ΅Π»ΡΡΠ΅Ρ Π.Π.' Π¦ΠΈΡΠΎΠΊΠΈΠ½ΠΎΠ²ΡΠΉ ΡΡΠ°ΡΡΡ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΠΎΠ±ΡΡΡΡΠΊΡΠΈΠ²Π½ΡΠΌΠΈ Π±ΠΎΠ»Π΅Π·Π½ΡΠΌΠΈ Π»Π΅Π³ΠΊΠΈΡ ΠΈ Π΅Π³ΠΎ ΡΠ²ΡΠ·Ρ Ρ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΠΌ ΡΠΎΡΡΠΎΡΠ½ΠΈΠ΅ΠΌ ΠΊΠΎΡΡΠ½ΠΎΠΉ' ΡΠΊΠ°Π½ΠΈ.// Π’Π΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈΠΉ Π°ΡΡ ΠΈΠ², 2004, № 3, Ρ.23−27.
- ΠΠ΅ΠΏΠ°ΡΡΠΊΠΈΠΉ Π.Π., Π‘ΠΌΠΈΡΠ½ΠΎΠ² Π. Π., ΠΡΠ»ΠΎΠ² Π. Π. Π‘ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½Π°Ρ Π»ΡΡΠ΅Π²Π°Ρ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ° ΠΎΡΡΠ΅ΠΎΠΏΠΎΡΠΎΠ·Π°.//ΠΠ΅Π΄.Π²ΠΈΠ·ΡΠ°Π»ΠΈΠ·Π°ΡΠΈΡ, 1996, № 3, Ρ.9−17
- ΠΠΈΡ Π°ΠΉΠ»ΠΎΠ² Π.Π. ΠΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠ΅ ΠΈΠ·ΡΡΠ΅Π½ΠΈΠ΅ ΡΠ°ΡΡΠΎΡΡ Π½ΠΎΠ²ΡΡ ΠΏΠ΅ΡΠ΅Π»ΠΎΠΌΠΎΠ² ΠΊΠΎΡΡΠ΅ΠΉ ΠΏΠ΅ΡΠΈΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠΊΠ΅Π»Π΅ΡΠ° Π² ΠΏΠΎΠΏΡΠ»ΡΡΠΈΠΎΠ½Π½ΠΎΠΉ Π²ΡΠ±ΠΎΡΠΊΠ΅ Π»ΠΈΡ ΡΡΠ°ΡΡΠΈΡ Π²ΠΎΠ·ΡΠ°ΡΡΠ½ΡΡ Π³ΡΡΠΏΠΏ.// ΠΡΡΠ΅ΠΎΠΏΠΎΡΠΎΠ· ΠΈ ΠΎΡΡΠ΅ΠΎΠΏΠ°ΡΠΈΠΈ, 2002, № 3, Ρ. 2−5.
- ΠΠΈΡ Π°ΠΉΠ»ΠΎΠ² Π.Π., ΠΠ΅Π½Π΅Π²ΠΎΠ»Π΅Π½ΡΠΊΠ°Ρ Π. Π., ΠΡΠ»ΠΎΠ² Π. Π. Π Π°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΠΎΡΡΡ ΠΏΠ΅ΡΠ΅Π»ΠΎΠΌΠΎΠ² ΠΏΠΎΠ·Π²ΠΎΠ½ΠΎΡΠ½ΠΈΠΊΠ° Π² ΠΏΠΎΠΏΡΠ»ΡΡΠΈΠΎΠ½Π½ΡΠΎΠΉ Π²ΡΠ±ΠΎΡΠΊΠ΅ Π»ΠΈΡ 50 Π»Π΅Ρ ΠΈ ΡΡΠ°ΡΡΠ΅ //ΠΠ΅ΡΡΠ½. Π’ΡΠ°Π²ΠΌΠ°ΡΠΎΠ». ΠΈ ΠΎΡΡΠΎΠΏΠ΅Π΄, ΠΈΠΌ. Π. Π. ΠΡΠΈΠΎΡΠΎΠ²Π°, 1997, № 3, Ρ.20−27
- ΠΠΈΡ Π°ΠΉΠ»ΠΎΠ² Π.Π., ΠΠ΅Π½ΡΡΠΈΠΊΠΎΠ²Π° Π. Π., ΠΡΡΠΎΠ²Π° Π. Π. ΠΠΏΠΈΠ΄Π΅ΠΌΠΈΠΎΠ»ΠΎΠ³ΠΈΡ ΠΎΡΡΠ΅ΠΎΠΏΠΎΡΠΎΠ·Π° ΠΈ ΠΏΠ΅ΡΠ΅Π»ΠΎΠΌΠΎΠ² Π² Π ΠΎΡΡΠΈΠΈ.//Π’Π΅Π·ΠΈΡΡ Π ΠΎΡΡΠΈΠΉΡΠΊΠΎΠ³ΠΎ ΠΊΠΎΠ½Π³ΡΠ΅ΡΡΠ° ΠΏΠΎ ΠΎΡΡΠ΅ΠΎΠΏΠΎΡΠΎΠ·Ρ 20−22 ΠΎΠΊΡΡΠ±ΡΡ 2003 Π³. Π³. ΠΠΎΡΠΊΠ²Π°.
- ΠΡΠΈΠ»Π΅ΠΏΡΠΊΠ°Ρ Π.Π., ΠΠ΅Π΄ΠΈΠ½Π° Π. Π., ΠΠ°Π»ΡΡΠ΅Π²Π° Π. Π., ΠΡΠΎΠΆΠΆΠΈΠ½Π° Π. Π. ΠΠΎΡΡΠΌΠ΅Π½ΠΎΠΏΠ°ΡΠ·Π°Π»ΡΠ½ΡΠΉ ΠΎΡΡΠ΅ΠΎΠΏΠΎΡΠΎΠ·, ΠΊΠΎΠ½ΡΡΠ°ΡΠ΅ΠΏΡΠΈΡ ΠΈ Π·Π°ΠΌΠ΅ΡΡΠΈΡΠ΅Π»ΡΠ½Π°Ρ Π³ΠΎΡΠΌΠΎΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΡ.// Consilium-medicum, 2000, ΡΠΎΠΌ 2, № 6, Ρ.257−260.
- Π ΠΎΠΆΠΈΠ½ΡΠΊΠ°Ρ Π.Π―. Π‘ΠΈΡΡΠ΅ΠΌΠ½ΡΠΉ ΠΎΡΡΠ΅ΠΎΠΏΠΎΡΠΎΠ·. ΠΠΎΡΠΊΠ²Π°: ΠΠ ΠΠ-ΠΠ ΠΠ‘Π‘, 1996, Ρ. 208
- Π ΡΠ±ΠΈΠ½ Π.Π., Π§Π΅ΡΡΡΠΈΠ½ Π . Π. ΠΠ²ΡΡ ΡΠ½Π΅ΡΠ³Π΅ΡΠΈΡΠ΅ΡΠΊΠ°Ρ ΡΠ΅Π½ΡΠ³Π΅Π½ΠΎΠ²ΡΠΊΠ°Ρ Π°Π±ΡΠΎΡΠ±ΡΠΈΠΎΠΌΠ΅ΡΡΠΈΡ ΠΎΡΠ΅Π²ΠΎΠ³ΠΎ ΡΠΊΠ΅Π»Π΅ΡΠ°: ΠΌΠ΅ΡΠΎΠ΄ΠΈΠΊΠ° ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ, Π°Π½Π°Π»ΠΈΠ·Π° ΠΈ ΠΏΡΠΎΡΠΎΠΊΠΎΠ»ΠΈΡΠΎΠ²Π°Π½ΠΈΡ.// Π Π°Π΄ΠΈΠΎΠ»ΠΎΠ³ΠΈΡ ΠΈ ΠΏΡΠ°ΠΊΡΠΈΠΊΠ°, 2001, № 2, Ρ. 34−41.
- Π’ΠΎΡΠΎΠΏΡΠΎΠ²Π° Π.Π. ΠΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠ° ΠΏΠΎΡΡΠΌΠ΅Π½ΠΎΠΏΠ°ΡΠ·Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΎΡΡΠ΅ΠΎΠΏΠΎΡΠΎΠ·Π° ΡΠΎΠ»Ρ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² ΠΊΠ°Π»ΡΡΠΈΡ ΠΈ Π²ΠΈΡΠ°ΠΌΠΈΠ½Π° D.// Consilium-medicum. ΠΠΈΠ½Π΅ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠ°Ρ ΡΠ½Π΄ΠΎΠΊΡΠΈΠ½ΠΎΠ»ΠΎΠ³ΠΈΡ, 2005, ΡΠΎΠΌ 7, № 9, Ρ. 792−797
- Π’ΠΎΡΠΎΠΏΡΠΎΠ²Π° Π.Π., ΠΠ΅Π½Π΅Π²ΠΎΠ»Π΅Π½ΡΠΊΠ°Ρ Π. 14. ΠΡΡΠ΅ΠΎΠΏΠΎΡΠΎΠ· Π² ΠΏΡΠ°ΠΊΡΠΈΠΊΠ΅ ΡΠ΅ΠΌΠ΅ΠΉΠ½ΠΎΠ³ΠΎ Π²ΡΠ°ΡΠ°. // Π ΠΠ, 2004, ΡΠΎΠΌ 12, № 12, Ρ. 715−717.
- Π§Π΅ΡΡΡΠΈΠ½ Π .Π., ΠΠΌΠ΅ΡΠΎΠ² Π. Π‘., Π ΡΠ±ΠΈΠ½ Π. Π. Π‘ΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½Π°Ρ ΠΎΡΠ΅Π½ΠΊΠ° ΡΠ΅Π½ΡΠ³Π΅Π½ΠΎΠ²ΡΠΊΠΎΠΉ Π΄Π΅Π½ΡΠΈΡΠΎΠΌΠ΅ΡΡΠΈΠΈ ΠΎΡΠ΅Π²ΠΎΠ³ΠΎ ΡΠΊΠ΅Π»Π΅ΡΠ° ΠΈ ΡΠ»ΡΡΡΠ°Π·Π²ΡΠΊΠΎΠ²ΠΎΠΉ Π΄Π΅Π½ΡΠΈΡΠΎΠΌΠ΅ΡΡΠΈΠΈ ΠΏΡΡΠΎΡΠ½ΠΎΠΉ ΠΊΠΎΡΡΠΈ.// ΠΡΡΠ΅ΠΎΠΏΠΎΡΠΎΠ· ΠΈ ΠΎΡΡΠ΅ΠΎΠΏΠ°ΡΠΈΠΈ, 1999, № 4, Ρ. 7−10.
- Π§ΡΡΠ°Π»ΠΈΠ½ Π.Π. ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°ΡΠΈΠΈ ΠΏΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΎΠ±ΡΡΡΡΠΊΡΠΈΠ²Π½ΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΡΡ Π»Π΅Π³ΠΊΠΈΡ ΠΠΈΠ½ΠΈΡΡΠ΅ΡΡΡΠ²ΠΎ Π·Π΄ΡΠ°Π²ΠΎΠΎΡ ΡΠ°Π½Π΅Π½ΠΈΡ Π Π€ ΠΠ°ΡΡΠ½ΠΎ-ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΠ΅Π»ΡΡΠΊΠΈΠΉ ΠΈΠ½ΡΡΠΈΡΡΡ ΠΏΡΠ»ΡΠΌΠΎΠ½ΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΠ Π Π€ ΠΠΎΡΠΊΠ²Π°, 2002, Ρ. 65.
- Π§ΡΡΠ°Π»ΠΈΠ½ Π.Π. ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°ΡΠΈΠΈ ΠΏΠΎ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΡ ΠΎΠ±ΡΡΡΡΠΊΡΠΈΠ²Π½ΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΠΈ Π»Π΅Π³ΠΊΠΈΡ . ΠΠΈΠ½ΠΈΡΡΠ΅ΡΡΡΠ²ΠΎ Π·Π΄ΡΠ°Π²ΠΎΠΎΡ ΡΠ°Π½Π΅Π½ΠΈΡ-Π Π€. ΠΠΎΡΠΊΠ²Π°' 2001, Ρ. 40.
- Π¨ΠΎΡΡΠ°ΠΊ Π.Π. ΠΡΡΠ΅ΠΎΠΏΠΎΡΠΎΠ·. Π‘ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠ΅ Π°ΡΠΏΠ΅ΠΊΡΡ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ.// ΠΠ΅ΡΠ°ΡΠΈΠΉ Π²ΡΠ°Ρ, 2004, № 7, Ρ. 26−29.
- Adinoff A.D., Hollister J.R. Steroid-induced fractures and bone loss in patients with asthma// N. Engl. J. Med.: 1983, 309, p. 265−268.
- Aris R.M., Neuringer I.P., Weiner M.A. et al. Severe osteoporosis before and after lung transplantation.// Chest: 1996, 109, p. 1176−1183.
- Barnes N.C. Safety of high-dose inhaled corticosteroids // Respir. Med.: 1993, voll.87, p. 27−31.
- Bernard S., LeBlanc P., Whittom F., Carrier G. Jobin* J., Belleau R., Maltais F. Peripheral muscle weakness in patients with- chronic obstructive pulmonary disease.// Am. J. Respir. Crit. Care Med.: 1998, 158, p. 629−634.
- Bischoff-Ferrari H.A., et al. Effect of vitamin D on falls: a meta-analysis.// JAMA.: 2004, 291, p. 1999−2006.
- Black D.M., Arden N.K., Palermo L., Pearson J., Cummings Sr. 1999 Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures.// J. Bone. Miner. Res.: 1999, 14, p. 821−828.
- Black P.N. and Scragg R. Relationship between serum 25-hydroxyvitamin D and pulmonary function in the third national health nutrition examination survey.// Chest: 2005, 128, p. 3792−3798.
- Carter R., Blevins W., Stocks J., et al. Cost and quality issues related to the management of COPD.// Sem. Resp. Crit. Care Med.: 1999, 20, p. 199−212.
- Churg A., Dai J., Tai H., Xie C. tumor necrosis factor-alpha is central to acute cigarette smoke-induced inflammation and connective tissue breakdown.// Am.J.Respir. Crit. Care Med.: 2002- 166 (6): p. 849−854.
- Cloth F.M., Gundberd C.M., Hollis B.W. et al. Vitamin D deficiency in homebound elderly persons//JAMA: 1995, 274, p. 1683−1686.
- Cooper C., Campion1 G., Melton III L.J. Hip fractures in the elderly: a world-wide projection.// Osteoporosis int.: 1992, 2, p. 285−289.
- Coronado M., Fitting J.W. Extrapulmonary effects of chronic obstructive pulmonary disease.// Rev. Med. Suisse.: 2005 Nov 16, 1(41), p. 2680−2682, p. 26 852 687.
- Decramer M., Lacquet L.M., Fagard R., Rogiers P. Corticosteroids contribute to muscle weakness in chronic airflow obstruction.// Am. J. Respir. Crit. Care Med.: 1994, 150, p. 11−16.
- DiFrancia M., Barbier D., Mege J.L., et al Tumor necrosis factor levels and weight loss in chronic obstructive pulmonary disease.// Am. J. Respir. Crit. Care Med.: 1994, 150, p. 1453−1455.
- Dubois E.F.- Roder E.- Dekhuijzen P.N.Richard- Zwinderman A.E. and Schweiter D.H. Dual energy X-ray absorptiometry outcomes in male COPD patients after treatment with different glucocorticoid regimens// Chest.: 2002, 121, p. 14 561 463.
- Eastell R., Reid D.M., Compston J. et al. A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update // J. intern. Med.: 1998, vol.244, p. 271−292.
- Ensrud K.E., Nevitt M.C., Palermo L., et al. What proportion of incident morthometric vertebral fractures are clinically diagnosed and vice versa?// J. Bone Miner. Res.: 1999,14 (Suppl), p. 138.
- Falahati-Nini A., Riggs B.L., Atkinson E.J., O’Fallon W.M., Eastell R., Khosla S. Relative contributions of testosterone and estrogen in regulating bone resorbtion and formation in normal elderly men.// J. Clin. Invest.: 2000, 106, p. 15 531 560.
- Goldstein M.F., J. Fallon J., and Harning R. Chronic glucocorticoid therapy-induced osteoporosis in patients with obstructive lung diseas// Chest.: 1999, 116, p. 1733−1749.
- Gosselink R., Troosters Π’., Decramer M. Peripheral muscle weakness contributes to exercise limitation in COPD.// Am. J. Respir. Crit. Care Med.: 1996, 153, p. 976−980.
- Greenspan S.L., Von Stetten E., Emond S.fC., Jones, BS Lisa, and Parker R.A. Instant vertebral assessment// Journal of clinical densitometry: 2001 Winter, vol.4, № 4, p. 373−380.
- Gupta R.P., Hollis B.W., Patel S.B., Patrick K.S., Bell’N.H. CYP3A4 is a human microsomal vitamin D 25-hydroxylase.// J. Bone Miner Res.: 2004 Apr- 19(4), p. 680−688. Epub 2003 Dec 22.
- Guttridge D.C., Mayo M.W., Madrid L.V., Wang C.Y., Baldwin A.S. NF-aB induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia.// Science.: 2000, 289, p. 2363−2366.
- Hamilton A.L., Killian K.J., Summers E., Jones N.L. Muscle strength, symptom intensity, and exercise capacity in patients with Car-disorespiratory disorders.//Am. J. Respir. Crit. Care Med.: 1995, 152, p. 2021−2031.
- Harrison T.W., Wisniewski A., Honour J., Tatterfield A.E. Comparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler in healthy and asthmatic subjects.// Thorax: 2001, 56(3), p. 186−191.
- Herrala J., Puolijoki H., Impivaara O., Liipo K., Tala E., Nieminen MM. Bone mineral density in asthmatic women on high-dose inhaled beclomethasone dipropionate.// Bone.: 1994Nov-Dec, 15(6), p. 621−623.
- Hill A.T., Beyley D.I., Campbell E. J et al. Airways inflammation in chronic bronchitis- the effect of smoking and alpha-antitrypsin deficiency.// Eur. Respir. J.: 2000, 15 (5), p. 886−890.
- Howald H., Pette D., Simoneau J.A., Uber A., Hoopler H., Cerretelli P. Effect of chronic hypoxia on muscle enzyme activities.// Int. J. Sports Med.: 1990, 11, p. 510−514.
- Hubbard R.B., Smith Π‘ .J., Smeetli L, et al. Inhaled corticosteroids and hip fractures, a population-based case-control study.//Ibid.: 2002, vol.166, p. 1563−1566.
- Incalzi R.A., Caradonna P, Ranieri P. et al. Correlates of osteoporosis in chronic obstructive pulmonary disease.// Respir. Med: 2000, 94, 1079−1084.
- Iqbal F., Michaelson J., Thaler L., Rubin J., Roman J., and Nanes M.S. Declining bone mass in men with chronic pulmonary disease. Contribution of glucocorticoid treatment, body mass index, and gonadal function.// Chest: 1999, 116, p. 1616−1624.
- Israel E., Banerjee T.R., Fitzmaurice G.M., Kotlov T.V., LaHive K., LeBoff M.S. Effects of inhaled glucocorticoids on bone density in premenopausal women.//N. Engl. J. Med.: 2001, September 27, 345, p. 941−947.
- Jenkins M.R., Denison A.V. Smoking stains as a predictor of hip fracture risk in postmenopausal women of northwest Texas.// Prev. Chronic Dis.: 2008 Jan, 5(1), A09. Epub 2007 Dec 15.
- Jobin J., Maltais F., Doyon J.F., LeBlanc P., Simard P.M., Simard A.A., Simard. Chronic obstructive pulmonary disease capillarity and fiber-type characteristics of skeletal muscle.// J. Cardiopulm. Rehab.: 1998, 18, p. 432−437.
- Johnell O., de Laet C., Johansson H., et al. Oral corticosteroids increase fracture risk independently of BMD. // Osteoporos. Int.: 2002, vol.13, Suppl. I, p. 14.
- Johnell O., Pauwels R., Lofdahi C.G. et al Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler./ZEur.respirJ.: 2002, vol.19, № 6, p. 1058−1063.
- Johnston C.C., Melton L.J., Lindsay R., et al. Clinical indication for bone mass measurements.// J. Bone Miner. Res.: 1989, 4, p. 1345−1350.
- Jones A., Fay J.K., Burr M., et al. Inhaled corticosteroid effects on bone metabolism in asthma and mild obstructive pulmonary disease.// Cochrane Library: 2002- 3: CD003537.
- Jorgensen N.R., Schwarz P., Holme I., Henriksen B.M., Petersen L.J., Backer V. The- prevalence of osteoporosis in patients with chronic obstructive pulmonary disease: A cross sectional study.//Respiratory medicine: 2007 Jan, 101(1), p. 177−185.
- Kao P.C., Heser D.W. Simultaneous determination of 25-hydroxy- and 1.25-dihydroxyvitamin D from a single sample by dual-cartridge extraction.// Clin.Chem.: 1984, 30, p. 56−6.
- Karadag F., Cildag O., Yurekli Y., Gurgey O. Should COPD patients be routinely evaluated for bone mineral density?// J. Bone Miner. Metab.: 2003, 21(4), p. 242−246.
- Katsura H., Kida K.A. A comparison of bone mineral density in elderly female patients with COPD and bronchial asthma.// Chest.: 2002, 122, p. 1949−1955.
- Keatings V., Jatakanon A., Worsdell Y., Barnes P. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD.// Am. J. Respir. Crit. Care Med.: 1997, 548, p. 155.
- Kong Y.Y. molecular control of bone remodeling and osteoporosis.// Exp.Gerontol.: 2000, 35(8), p. 947−956.
- Laatikainen A.K., Kroger H.P.J., Tukiainen H.O., Honkanen R.J. and Saarikoski S.V. Bone mineral density in perimenopausal women with asthma.// Am.J.Respir.Crit.Care Med.: 1999 April, vol. 159, № 4, p. 1179−1185.
- Law M.R., Hackshaw A.K. A meta-analysis of sigarette smoking, bone mineral density and risk of hip fracture: recognition of a major effect.// B.M.J.: 1997, 315, p. 841−846.
- Layne M.D., Farmer S.R. Tumor necrosis factor-alpha and basis fibroblast growth factor differentially inhibit the insulin-like growth factor-I induced expression of myogenin in C2C12 myoblast.// Exp. Cell Res.: 1999, 249, p. 177−187.
- Lee T.A., Weiss K.B. Fracture risk assotiated with inhaled corticosteroid use in chronic obstructive pulmonary disease.// Am. J. Respir. Crit. Care Med.: 2004, 169, p. 855−859.
- Leech J.A., Dulberg C., Kellie S., Pattee L., Gay J. relationship of lung function to severity of osteoporosis in women.// Am. Rev. Respir. Dis.: 1990, 141, p. 68−71.
- Lo Cascio V., Bonucci E., Imbimbo Π., et al (1990) Bone loss in response to long-term glucocorticoid therapy.// Bone Miner.: 1990, 8, p. 39−51.
- Luengo M., Picado C., Del Rio L., et al. Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study.// Thorax.: 1991,46(11), p. 803−806.
- MacAdams M.R., White R.H., Chipps B.E. Reduction of serum testosterone levels during chronic glucocorticoid therapy // Ann. intern. Med.: 1986, vol.104, p. 648−651.
- Maltais F., Sullivan M.J., LeBlanc P., Duscha B.D., Schachat F.H., Simard C., Blank J.M., Jobin J. Altered expression of myosin heavy chain in the vastus lateralis muscle inpatients with COPD.//Eur. Respire. J.: 1999, 13, p. 850−854.
- Manino D.M., ΠΠΎΡΠ° D.M., Akinbami L.J., Moorman J.E., Gwynn C., Redd S.C. Surveillance for asthma United States, 1980−1999. MMWR Surveill Summ. 2002, 51, p. 1−13.
- Manolagas S.C. Role of cytokines in bone resorption.// Bone: 1995, 17(suppl), p. 63−67.
- Marie P., Ammann P., Shen V., Bain S., Robin Π., Dupin-Roger I. Evidence that strontium panelate increases bone quality in rats by improving bone strength and architecture.// Bone: 2003 May, vol. 32, Issue 5 (Supplement 1), p. S80. Abstr.
- Marshall D., Johnell O., Wedel H. Meta-analyses of how well measures of bone mineral density predict the occurrence of osteoporosis fractures.// B.M.J.: 1996, 312, p.1254−1259.
- Mazess R.B., Barden H.S. Bone density in premenopausal women: effect of age, dietary intake, physical activity, smoking, and birth-control pills.// American Journal of clinical nutrition: 1991, vol. 53, p. 132−142
- Melton L.J. Ill, Lane A.W., Cooper G., Eastell’R., O’Fallon W.M.,.Riggs B.L. Prevalence and incidence of vertebral fractures.// Osteoporosis Int.: 1993, 3, p. 113−119.
- Meunier P.J., Roux C., Ortolani S et al. Strontium ranelate reduces, the vertebral fracture risk in women with postmenopausal osteoporosis.// Osteoporos Int.: 2002, 13, p. 45.
- Mineo T.C., Ambrogi V., Mineo D., et al. Bone Mineral Density Improvement After Lung Volume Reduction Surgery for Severe Emphysema//Chest.: 2005, 127, p. 1960−1966.
- National Center for Health Statistics: current estimates from the National Health Interview Survey. Vital and Health Statistics, 1993, 10, p. 95−1518.
- O’Neil T.W., Felsenberg D. Varlow J., Cooper C., Kanis J.A., Silman A.J. 1996 The prevalence of vertebral fracture in European men and women: the European Vertebral Osteoporosis Study.// J. Bone Miner. Res.: 1996, 11, p. 10 101 018.
- Pawels R.A., Lofdahl C.G., Laitinen L.A. et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking.//N. Engl. J. Med.: 1999, 340, p. 1948−1953.
- Praet J.P., Peretz A., Rosenberg S. Et al. Risk osteoporosis in men with chronic bronchitis.// Osteoporosis Int.: 1992, 2, p. 257−261.
- Reginster J.Y., Deroisy R., Jupsin I. Strontium ranelate. A new paradigm in the treatment of osteoporosis.// Drugs today: 2003, vol.39(2), p. 89−101
- Reginster J.Y., Sawicki A., Devogelaer J.P. et al. Strontium ranelate reduces the risk of hip fracture in women with postmenopausal osteoporosis.//Osteoporosis Int.: 2002, 13, p. 14.
- Reid M. B, Li Yi-Ping. Tumor necrosis factor- a and muscle wasting: a cellular perspective.// Respir. Res.: 2001, 2(5), p. 269−272.
- Riancho J.A., J. Gonzalez Macias, Π‘ Del Arco, JA Amado, J Freijanes and MA Anton Vertebral compression fractures and mineral metabolism in chronic obstructive lung disease.// Thorax: 1987, vol. 42, p. 962−966.
- Ross P.D., Davis J.W., Epstein R.S., Wasnich R.D. Pre-existing fractures and bone mass predict vertebral fracture incidence in women.// Ann. Intern. Med.: 1991,114: p. 919−923.
- Ross P.D., Genant H.K., Davis J.W., Miller P.D., Wasnich R.D. Predicting vertebral fracture incidence from prevalent fractures and bone density among non-black, osteoporotic women.// Osteoporosis Int.: 1993, 3, p. 120−126.
- Saito J.K., Davis J.W., Wasnich R.D., Ross P.D. Users of low dose glucocorticoids have increased bone rates, a longitudinal study.// Calcif. Tissue Int.: 1995, 57(2), p. 115−119.
- Sambrook P.N., et al. Serum parathyroid hormone predicts time to fall independent of vitamin D status in a frail elderly population.// J. Clin. Endocrinol. Metab.: 2004, 89, p. 1572−1576.
- Seeman E. Pathogenesis of bone fragility in women and men.// Lancet: 2002, 359, p. 1841−1850.
- Seeman E., Melton L.J., O’Fallon W.M. et al. Risk factors for spinal osteoporosis in men.// Am. J. Med.: 1983, 75, p. 977−983.
- Shane E., Silverberg S.J., Donovan D., et al. Osteoporosis in lung transplantation candidates with end-stage pulmonary disease.// Am. J. Med.: 1996, 1015, p. 262−269.
- Sharma S., Fraser M., Lovell F., Reece A., McLellan A.R. Characteristics of males over 50 years who present with a fracture: epidemiology and underlying risk factors.// J. Bone Joint. Surg. Br.: 2008 Jan, 90(1), p. 72−77.
- Shea J.E., Miller S.C., Poole D.C., Mattson J.P. Cortical bone dynamics, strength, and densitometry after induction of emphysema in hamsters.// J. Appl. Physiol: 2003, 95, p. 631−634.
- Sinn D.D., Man J.P., Man S.F. The risk of osteoporosis in Caucasian men and women with obstructive airways disease.// Am. J. Med.: 2003, 114, p. 10−14.
- Slemenda C.W., Hui S.L., Longscope C., Johnston C.C. Cigarette smoking, obesity and bone mass.// J. Bone Miner. Res.: 1989, 4, p. 737−741.
- Stevenson JC, Lees B, Devenport M, et al Determinants of bone density in normal women: risk factors for future osteoporosis?// B.M.J.: 1989, 298, p. 924−928.
- Storm Π’., Thamsborg G., Steiniche Π’., GenantH.K., Sorensen O.H. Effect of intermitten cyclical etidronate therapy on bone mass and fracture rate in women1 with postmenopausal osteoporosis.//N. Engl. J. Med: 1990, 322″, p. 1265−1271.
- Suissa S, Baltzan M, Kremer R et al. Inhaled and nasal corticosteroid-use and the risk of fracture// Am. J. Respir. Crit. Care Med.: 2004, 169, p. 83−88.
- Sutherland E.R., Allmers H., Ayas N.T., Venn A.J., Martin R.J. Inhaled corticosyeroids reduce the progression' of airflow limitation' in chronic obstructive pulmonary disease: a meta-analysis.// Thorax.: 2003″, 58, p. 937−941.
- Szekely L.A., Oelberg D.A., Wright C., et al. Preopertaive predictors of operative morbidity andi mortality in COPD patients undergoing bilateral lung volume reduction surgery.// Chest.: 1997, 111, p. 550−558.
- Thaloor D., Miller K.J., Gephart J., Mitchell P.O., Palvath G.K. Systemic administration of the NF- aB' inhibitor curcumin stimulates muscle regenerations aftertraumatic injury.// Am. J. Physiol.: 1999- 277, p. 230−239-
- Van Staa T.P., Laan R.F., Barton I.P. et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy//Arthritis Rheum.: 2003, vol.48, 11, p. 3224−3229.
- Van Staa T.P., Leufkens H.G., Cooper C. Use of inhaled corticosteroids and risk of fractures.// J. Bone Miner.Res.: 2001, vol. 16, p. 581−588.
- Vestergaard P., Rejnmark L., and Mosekilde L. Fracture risk in patients with chronic lung diseases treated with bronchodilatator drugs and inhaled and oral corticosteroids.//Chest.: 2007, 132, p. 1599−1607.
- Watz Y., Magnussen H. Comorbidities of COPD// Internist (Berl).: 2006 Sep, 47(9), p. 898−900.
- Wise R., Connet J., Weinmann G., et al. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease.// N Engl. J. Med.: 2000, 343, p. 1902−1909.
- Wong P.K., Christie J.J., Wark J.D. The effects of smoking on bone health.// Clin. Sci (Lond).: 2007 Sep, 113(5), p. 233−241.